Comparison between subcision followed by 35% TCA versus subcision followed by microneedling in the treatment of acne scars: a prospective comparative study. - Trial PACTR201812717126560
Access comprehensive clinical trial information for PACTR201812717126560 through Pure Global AI's free database. This Phase 4 trial is sponsored by Dermatology department and is currently Completed. The study focuses on Skin and Connective Tissue Diseases.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dermatology department
Sarah Orabi
Timeline & Enrollment
Phase 4
Jan 01, 1900
Jan 01, 1900
Summary
Background:Acne scars treatment is difficult and challenging because of the variety in the acne scars morphology and the limited ability of the available treatment options to improve the scars. Multiple treatment modalities are used and each has its unique place in the treatment plan. Subcision is a non operative procedure that aims to break the fibrous strands that tether the scar to the underlying subcutaneous tissue, in which a needle is inserted through a puncture in the skin surface and passed in multiple directions to create a pocket under the scar to release the fibrous attachments.Microneedling, which is also known as percutaneous collagen induction therapy or needle dermabrasion, is a skin resurfacing procedure which involves the use of fine needles that create micro skin wounds. Trichloroacetic acid (TCA) causes protein denaturation named keratocoagulation resulting in white frost. 35% is used for medium depth peeling.Objective:To compare the efficacy and safety of both combined subcision and microneedling versus combined subcision and peeling in the treatment of acne scars.
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR201812717126560
Non-Device Trial

